Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-02-12
1998-12-01
Fay, Zohreh
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514558, A61K 3140, A61K 3120
Patent
active
058439790
ABSTRACT:
Methods and compositions for inhibiting or preventing the skin irritating or sensitizing effects of a skin irritating or sensitizing component of a dermal or transdermal drug delivery system are disclosed. The composition comprises a mast cell degranulating agent which is capable of inducing a state of immunological tolerance to the skin sensitizing agent by delivery prior to, or at the onset of transdermal drug delivery. Such an agent, preferably cis-urocanic acid or an analogue or metabolite thereof, can be administered before, during or after each transdermal drug delivery to achieve immune tolerance countersensitization. Alternatively, the agent can be used to induce countersensitization. The agent is preferably capable of permeating the epidermis and is administered transdermally. Novel methods and compositions comprising cis-urocanic acid or an analogue or metabolite thereof to obtain anti-inflammatory effects are also disclosed.
REFERENCES:
patent: 455036 (1995-10-01), Stab et al.
patent: 485154 (1989-12-01), Cormier
patent: 500956 (1991-03-01), Amkraut
patent: 4897260 (1990-01-01), Ross
patent: 5028431 (1991-07-01), Franz
patent: 5049387 (1991-09-01), Amkraut
patent: 5077054 (1991-12-01), Amkraut
patent: 5118509 (1992-06-01), Amkraut
patent: 5120545 (1992-06-01), Ledger
patent: 5130139 (1992-07-01), Cormier
patent: 5296225 (1994-03-01), Adekunle et al.
S. Gruner, H. Oesterwitz, H. Stoppe, W. Henke, R. Eckert, and N. Sonnichsen. Cis-Urocanic Acid as a mediator of ultraviolet light-induced immunosuppression. Seminars in Hematol. 29:(2), 102-107, 1992.
S. Gruner, W. Diezel, H. Stoppe, H. Oesterwitz and W. Henke. Inhibition of skin allograft rejection and acute graft-versus-host disease by cis-urocanic acid. J. Invest. Dermatol. 98: 459-462, 1992.
R. H. Guymer and T.E. Mandel. Urocanic acid and allotransplantation. Transplant. Proc. 22 (5) ; 2119-2120, 1990.
T.G. Harriot-Smith and W.J. Halliday. Suppression of contact hypersenitivity by short-term ultraviolet irradiation: II. The role of urocanic acid. clin. exp. Immunol. 72: 174-177, 1988.
I. Kurimoto and J. W.. Streilein. Cis-urocanic acid suppression of contact hypersenitivity induction is mediated via tumor necrosis factor-.alpha.. J Immunol. 148: 3072-3078, 1992.
I. Kurimoto and J. W. Streilein. Deleterious effects of cis-urocanic acid and UVB radiation on Langerhans cells and on induction of contact hypersensitivity are mediated by tumor necrosis factor-alpha. J. Invest. Dermatol., 99: 69S-70s, 1992.
W.L. Morison and S.P. Kelley. Urocanic acid may not be the photoreceptor for UV-induced suppression of contact hypersensitivity. Photodermatol. 3: 98-101, 1986.
A.M. Moodycliffe, I. Kimber and A.M. Norval. The effect of ultraviolert B irradiation and urocanic acid isomers on dendritic cell migration. Immunology 77: 394-399, 1992.
F.P. Noonan, E.C. De Fabo and H. Morrison. Cis-urocanic acid, a product formed by ultraviolet B irradiation of the skin, initiates and antigen presentation defect in splenic dendritic cells in vivo. J. Invest. Dermatol. 90: 92-99, 1988.
F.P. Noonan and E.C. De Fabo. Immunosuppression by ultraviolet B radiation: initiation by urocanic acid. Immunology Today 13 (7) : 250-254, 1992.
M. Norval, J. W. Gilmour and T.J. Simpson. The effect of histatmine receptor antagonists on immunosuppression indcued by the cis-isomer of urocanic acid. Phortodermatol Photoimmunol. Photomed. 7: 243-248, 1990.
M. Norval, T.J. Simpson and J.A. Ross. Urocanic acid and immunosuppression. Photochem & Photobiol., 50(2) : 267-273, 1989.
M. Norval, J.T. Simpson, E. Bardsihri and S. E. Howie. Urocanic acid analogues and the suppression of the delayed-type hypersensitivity response to Herpes simplex virus. Photochem. & Photobiol. 49(5) : 633-639, 1989.
E.W. Palaszynski, F.P. Noonan and E.C. De Fabo. Cis-urocanic acid down-regulates the induction of adenosine 3', 5'-cyclic monophosphate by either trans-urocanic acid or histamine in human dermal fibrtoblasts in vitro. Photochem. & Photobiol. 55(2) : 165-171, 1992.
L. Rasanen, C.T. Jansen, T. Reunala and H. Morrison. Stereospecific inhibition of human epidermal cell interleukin-1 secretion and HLA-DR expression by cis-urocanic acid. Photodermatol. 4: 182-186, 1987.
V. E. Reeve, G.E. Greenoak, P.J. Canfield, C. Boehm-Wilcox, and C.H. Gallagher. Topical urocanic acid enhances UV-induced tumor yield and malignacy in the hairless mouse. Photochem. & Photobiol., 49 (4) : 459-464, 1989.
V.E. Reeve and L.E. Mitchell. Hazards of urocanic acid as a cosmetic ingredient. Photodermatol Photoimmuno. Photomed. 8: 176-180, 1991.
V.E. Reeve, M. Bosnic and E. Rozinova. Carnosine (.beta.-alanylhistdine ) protects from the suppression of contact hypersensitivity by ultraviolet B (280-320 nm,) radiation oir by cis-urocanic acid. Immunology 78: 99-104, 1993.
J.A. Ross, S.E. Howie, M. Norval, J. Maingay and T.J. Simpson. Ultraviolet-irradiated urocanic acid suppresses delayed type hypersensitivity to herpes simplex virus in mice. J. Invest. Dermatol. , 87: 630-633, 1986.
J.A. Ross, S.E. Howie, M. Norval and J.P. Maingay. Induction of suppression of delayed-type hypersensitivity to herpes simplex virus by epidermal cells exposed to UV-irradiated urocanic acid in vivo. Viral Immunol. 1(3): 191-197, 1987.
J. A. Ross et al., Two Phenotypically Distinct T Cells are Involved in Ultraviolet-Irradiated Urocanic Acid-Induced Suppression of the Efferent Delayed-Type Hypersensitivity Response to Herpes Simplex Virus, Type 1 In Vivo, J. Invest. Derma., vol. 89, No. 3, pp. 230-233 (1987).
Kydonieus Agis F.
Wille John J.
Bristol--Myers Squibb Company
Fay Zohreh
Furman Jr. Theodore R.
Kilcoyne John M.
LandOfFree
Transdermal treatment with mast cell degranulating agents for dr does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Transdermal treatment with mast cell degranulating agents for dr, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transdermal treatment with mast cell degranulating agents for dr will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2396041